- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03480386
Home Pulmonary Rehabilitation for COPD
January 18, 2024 updated by: Roberto P. Benzo, Mayo Clinic
Regular physical activity has been found to be important in maintaining health and well-being in people with COPD.
The purpose of this study is to test new technology and health coaching aimed to help people with COPD become more physically active in their daily lives.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This study will test the effectiveness of a home-base pulmonary rehabilitation program, that includes off-the-shelf technology (Android computer tablet, Nonin pulse oximeter and Garmin Fitness Tracker), health coaching and an online platform that allows a health coach to review patient monitoring and progress.
The comparison will be a wait-list control group.
Study Type
Interventional
Enrollment (Actual)
375
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic in Florida
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55122
- Health Partners
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 99 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Clinical diagnosis of COPD, confirmed by spirometry
- Age ≥40 years (to avoid recruiting participants with asthma rather than COPD)
- Current or previous smoker (≥10 packs per year)
- Confidence in using the proposed pulmonary rehabilitation (PR) system
- English language fluency
Exclusion Criteria:
- Study candidate experiencing an acute COPD exacerbation (can be included after the acute event)
- Inability to walk (orthopedic-neurologic problems or confined to a bed)
- Currently in PR or finished PR in the last three months (unlikely to improve)
- Pregnant women
- Live in an area where cell phones do not work/
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Pulmonary Rehabilitation Program Intervention
Subjects will receive 12 weeks home pulmonary rehabilitation (PR) with health coaching.
|
Twice daily exercise routine six days a week of 3 minutes of personal breathing, 5 exercises with 10 reps each, and 6 minutes of walking with weekly health coach calls.
|
|
No Intervention: Usual Care
Subjects will receive 12 weeks of usual care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Quality of Life
Time Frame: Baseline, 3 months
|
The Chronic Respiratory Questionnaire (CRQ) is a validated tool, completed by participants at baseline and 3 months and measured health-related quality of life.
This questionnaire measures both physical and emotional aspects of chronic respiratory disease.
All scores have a range of 1 to 7, a higher number being better health-related quality of life.
We reported the difference between baseline and 3 months on the CRQ emotional summary score (comprised of the mastery and emotional domains) and the physical summary score (comprised of dyspnea and fatigue domains).
0.5 points is the minimal clinically important difference for this tool.
|
Baseline, 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Self-management Abilities
Time Frame: Baseline, 3 months
|
Measured using the Self-Management Ability Scale-30 item questionnaire to assess ability and function.
The SMAS consists of 30 items on four- and five-point Likert scales.
Total score ranging from 0 to 100 with higher score indicating a higher function and ability, better outcome.
|
Baseline, 3 months
|
|
Change in Physical Activity
Time Frame: Baseline, 3 months
|
The change in average daily activity (measured in minutes) for the top 3 to 5 most active days during the measured period.
Measured by the Actigraph GT3X .
|
Baseline, 3 months
|
|
Change in Daily Step Counts
Time Frame: Baseline, 3 months
|
Measured by the Actigraph wGT3X-BT worn for 7 days continuously to measure daily step count.
|
Baseline, 3 months
|
|
Change in Depression
Time Frame: Baseline, 3 months
|
Measured by the Patient Health Questionnaire-9 item questionnaire screening for depression.
Total score range from 0 to 27.
A higher score indicates that depression may be present.
|
Baseline, 3 months
|
|
Social Support
Time Frame: Baseline, 3 months
|
Measured by the Interpersonal Support Evaluation List (ISEL-12) a 12-item measure of perceptions of social support utilizing three different subscales designed to measure three dimensions of f perceived social support (appraisal support, beloning support, and tangible support).
Each dimension is measured by 4 items on a 4-point scale ranging from "Definitely True" to "Definitely False".
Total score range 0-36 with a higher score indicating greater social support.
|
Baseline, 3 months
|
|
Meaning in Life
Time Frame: Baseline, 3 months
|
Meaning in Life Questionnaire- 10 item questionnaire measuring the purpose, meaning and presence in life.
A higher score indicates a perception of higher meaning and purpose.
Scores range from 10-70, a higher score indicates a high perceived meaning and purpose in the respondents life.
|
Baseline, 3 months
|
|
Change in Sleep Quality
Time Frame: Baseline, 3 months
|
Measured using the Pittsburgh Sleep Quality Index to assess severity of sleep disturbances.
9 item questionnaire with total possible scores range from 0 to 21.
A lower score suggests a better quality of sleep and a higher score indicates a worse outcome/more severe symptoms of disturbance.
|
Baseline, 3 months
|
|
Change in Anxiety
Time Frame: Baseline, 3 months
|
Measured using the General Anxiety Disorder-2 item Questionnaire screening for anxiety.
Score ranges from 0 to 6.,A higher score suggests that anxiety is present.
|
Baseline, 3 months
|
|
Healthcare Utilization
Time Frame: 3 months
|
Number of subjects to have an emergency room visits or hospitalization.
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Roberto P Benzo, Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2019
Primary Completion (Actual)
February 16, 2022
Study Completion (Actual)
February 16, 2022
Study Registration Dates
First Submitted
February 26, 2018
First Submitted That Met QC Criteria
March 20, 2018
First Posted (Actual)
March 29, 2018
Study Record Updates
Last Update Posted (Estimated)
February 13, 2024
Last Update Submitted That Met QC Criteria
January 18, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-009449
- R01HL140486-01 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Emphysema
-
Pulmonx CorporationRecruitingEmphysema or COPD | Emphysema, PulmonaryUnited States, Australia, Austria, Denmark, France, Germany, Italy, Netherlands, Spain, United Kingdom
-
Heidelberg UniversityUnknown
-
Royal Brompton & Harefield NHS Foundation TrustCompletedHeterogeneous EmphysemaUnited Kingdom
-
Aeris TherapeuticsCompleted
-
Pulmonx CorporationCompleted
-
University Medical Center GroningenCompletedEmphysema or COPDNetherlands
-
Aeris TherapeuticsCompleted
-
University Medical Center GroningenRecruitingEmphysema or COPDNetherlands
-
Rabin Medical CenterUnknownPatients With Advanced Homogeneous EmphysemaIsrael
-
Aeris TherapeuticsWithdrawnAdvanced Upper Lobe Predominant Emphysema
Clinical Trials on Home Based Pulmonary Rehabilitation
-
Istanbul Medipol University HospitalRecruitingLung Diseases | Bronchiectasis | Lung Diseases, Interstitial | Pulmonary RehabilitationTurkey
-
Istanbul Medipol University HospitalCompletedEmphysema | Bronchoscopic Lung Volume Reduction | Hospital-based Pulmonary Rehabilitation | Home-based Pulmonary RehabilitationTurkey
-
ADIR AssociationEuropean Union; Hopital La Musse; Groupe Hospitalier du Havre; Centre Hospitalier... and other collaboratorsRecruitingChronic Obstructive Pulmonary Disease (COPD)France
-
La Trobe UniversityMonash University; The Alfred; Austin HealthCompletedChronic Obstructive Pulmonary DiseaseAustralia
-
Polytechnic Institute of PortoNippon Gases PortugalRecruiting
-
Mayo ClinicBoehringer IngelheimCompletedFibrotic Interstitial Lung DiseaseUnited States
-
Chang Gung Memorial HospitalCompleted
-
Monash UniversityUniversity of Melbourne; La Trobe University; Institute for Breathing and Sleep... and other collaboratorsActive, not recruitingChronic Obstructive Pulmonary DiseaseAustralia
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI)CompletedCOPD ExacerbationUnited States
-
Centre de Recherche de l'Institut Universitaire...Completed